Cullinan Oncology LLC (NASDAQ:CGEM) — Market Cap & Net Worth
Market Cap & Net Worth: Cullinan Oncology LLC (CGEM)
Cullinan Oncology LLC (NASDAQ:CGEM) has a market capitalization of $706.55 Million ($706.55 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10804 globally and #2669 in its home market, demonstrating a 3.71% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cullinan Oncology LLC's stock price $13.43 by its total outstanding shares 59076259 (59.08 Million). Analyse Cullinan Oncology LLC cash flow conversion to see how efficiently the company converts income to cash.
Cullinan Oncology LLC Market Cap History: 2021 to 2026
Cullinan Oncology LLC's market capitalization history from 2021 to 2026. Data shows change from $911.55 Million to $793.39 Million (-13.99% CAGR).
Index Memberships
Cullinan Oncology LLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.03% | #291 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1066 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.04% | #172 of 263 |
Weight: Cullinan Oncology LLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cullinan Oncology LLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cullinan Oncology LLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
48.12x
Cullinan Oncology LLC's market cap is 48.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $911.55 Million | $18.94 Million | -$65.04 Million | 48.12x | N/A |
Competitor Companies of CGEM by Market Capitalization
Companies near Cullinan Oncology LLC in the global market cap rankings as of May 4, 2026.
Key companies related to Cullinan Oncology LLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Cullinan Oncology LLC Historical Marketcap From 2021 to 2026
Between 2021 and today, Cullinan Oncology LLC's market cap moved from $911.55 Million to $ 793.39 Million, with a yearly change of -13.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $793.39 Million | +29.76% |
| 2025 | $611.44 Million | -15.02% |
| 2024 | $719.55 Million | +19.53% |
| 2023 | $601.99 Million | -3.41% |
| 2022 | $623.25 Million | -31.63% |
| 2021 | $911.55 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Cullinan Oncology LLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $706.55 Million USD |
| MoneyControl | $706.55 Million USD |
| MarketWatch | $706.55 Million USD |
| marketcap.company | $706.55 Million USD |
| Reuters | $706.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a … Read more